NCT01640990View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Intravenous Infusion of GW328267X in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 22, 2011

Primary Completion Date

December 9, 2011

Study Completion Date

December 9, 2011

Conditions
Lung Injury, Acute
Interventions
DRUG

Saline

30mins run-in period

DRUG

GW328267X (total dose of 12mcg)

8 mcg/h for 1.5 hours (total dose of 12mcg)

DRUG

GW328267X (total dose of 40mcg)

10 mcg/h for 4 hours (total dose of 40 mcg)

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01640990 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Intravenous Infusion of GW328267X in Healthy Volunteers | Biotech Hunter | Biotech Hunter